

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Agilent buys Proscia for \$270 M, advancing AI-enabled digital pathology and scientific intelligence

14 October 2026 | News

Acquisition seamlessly builds on Agilent's pathology portfolio expansion efforts



Agilent Technologies Inc. has entered into a definitive agreement to acquire Proscia®, a provider of digital pathology software for clinical and life-sciences customers, in an all-cash transaction valued at \$240 million in cash at closing and up to an additional \$30 million based on achieving future performance milestones.

Proscia is a leading independent provider of enterprise digital pathology software, serving as a key enabler to address emerging trends in the \$5 billion Pathology market.

Agilent and Proscia entered into a multi-year distribution agreement in September 2022 to offer a comprehensive digital diagnostic-pathology system. Today's announcement builds on Agilent's established pathology solutions and its partnership with Proscia.

This acquisition strengthens Agilent's existing leadership in pathology instrumentation and reagents, combining industry-leading diagnostic capabilities with Proscia's vendor-agnostic digital pathology platform and established customer base. Proscia's platform holds FDA 510(k) clearance for primary diagnosis.